TSC-204-C0702

N/A

Report date: 2023/01/28 14:40:35

Base Information

Drug NameTSC-204-C0702
Drug Alias NameTSC-204-C0702
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionMelanoma-associated antigen 1 modulators
TargetsMelanoma-associated antigen 1
Therapy Area/IndicationsSolid tumoursPenile NeoplasmsVulvar Neoplasms +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTScan Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTScan Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursPenile NeoplasmsVulvar Neoplasms +[16] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A